Elan Corp., Plc. and Wyeth decided to stop the ongoing clinical trails testing effect of 2.0 mg/kg dose of experimental Alzheimer's drug bapineuzumab.
Officials from both companies declared the discontinuation of the highest of the three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in patients with mild-to-moderate Alzheimer's disease, or AD, who do not carry the Apolipoprotein E4, or ApoE4, allele. However testing of the 0.5 mg/kg and 1.0 mg/kg doses in two Phase III trials will continue as planned.
A decade-long research conducted by the Tata Memorial Hospital, and backed by the Bill & Melinda Gates Foundation, has reached a noteworthy conclusion with regard to detection of cervical cancer.
Recent study revealed an association in germs in mouths and increased risk of heart disease. This study gave the clear indication that oral hygiene has effect on cardio-vascular health. 
Sedentary lifestyle and fa
Pfizer Inc (PFE. N) stopped a late-stage study of its drug Sutent. This study was evaluating effect of this drug on advanced breast cancer patients. Sutent is presently approved to treat kidney cancer and a type of gastrointestinal cancer. Company officials notified that three other Phase III trials and two mid-stage trials of Sutent are under way in advanced forms of the cancer. 
The recent case of contaminated pistachios shows the void in food testing laws. Setton Farms in Terra Bella, California, the second-largest pistachio processor in the United States, recalled 2 million pounds of pistachios that may have been contaminated with salmonella. 
